Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting systemYingying Hu, Xin Hai, Jian Gong et al.|International Immunopharmacology|2020Cited by 98
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%Julie R. Brahmer, Martin Reck, Sinéad Cuffe et al.|Annals of Oncology|2020Cited by 96
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting SystemYang Hu, Dan Mei, Ziyu Bai et al.|Journal of Diabetes Research|2020Cited by 54
A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor UseJuan Shen, Bin Zhao, Jincheng Yang|Diabetes Therapy|2019Cited by 25
Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world studyBin Zhao, Hui Pan, Juan Shen et al.|Journal of Diabetes Investigation|2020Cited by 18